NICE guidance
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care. Find out more about guidance.
- Guidance products
- Published guidance
- New guidance (last 6 months)
- Updated guidance (last 6 months)
Guidance by programme
-
NICE guidelines
Review the evidence across broad health and social care topics.
-
Technology appraisal guidance
Review clinical and cost effectiveness of new treatments.
-
Interventional procedures guidance
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Guidance being developed or updated
Quality standards
Quality standards set out the priority areas for quality improvement in health and social care. Find out more about quality standards.
NICE advice
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance. Find out more about advice.
- Advice products
- Published advice
- New advice (last 6 months)
- Updated advice (last 6 months)
Advice by programme
-
Medtech innovation briefings
Review the evidence and likely costs of medical devices and technologies.
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
NICE guidelines
Review the evidence across broad health and social care topics.
-
Pancreatic cancer in adults: diagnosis and management (NG85)
-
Suspected cancer: recognition and referral (NG12)
Quality standards
Set out priority areas for quality improvement in health and social care.
Technology appraisal guidance
Review clinical and cost effectiveness of new treatments.
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)
-
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Interventional procedures guidance
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
-
Irreversible electroporation for treating pancreatic cancer (IPG579)
-
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)
-
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)
-
Laparoscopic distal pancreatectomy (IPG204)
Medtech innovation briefings
Review the evidence and likely costs of medical devices and technologies.
In development
-
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413
-
Pancreatic cancer
-
Pancreatic cancer - capecitabine [ID389]
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
New guidance and advice
Guidance and advice added since February 2018
Putting guidance into practice
Shared learning
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 1 of 1 shared learning examples for this topic: